NASDAQ
EXEL

Exelixis Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Exelixis Inc Stock Price

Vitals

Today's Low:
$21.91
Today's High:
$22.228
Open Price:
$22.08
52W Low:
$14.87
52W High:
$22.47
Prev. Close:
$21.99
Volume:
1655773

Company Statistics

Market Cap.:
$6.34 billion
Book Value:
7.862
Revenue TTM:
$1.66 billion
Operating Margin TTM:
8.84%
Gross Profit TTM:
$1.55 billion
Profit Margin:
9.24%
Return on Assets TTM:
3.17%
Return on Equity TTM:
6.34%

Company Profile

Exelixis Inc had its IPO on 2000-04-07 under the ticker symbol EXEL.

The company operates in the Healthcare sector and Biotechnology industry. Exelixis Inc has a staff strength of 1,223 employees.

Stock update

Shares of Exelixis Inc opened at $22.08 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $21.91 - $22.23, and closed at $22.09.

This is a +0.45% increase from the previous day's closing price.

A total volume of 1,655,773 shares were traded at the close of the day’s session.

In the last one week, shares of Exelixis Inc have slipped by -2.86%.

Exelixis Inc's Key Ratios

Exelixis Inc has a market cap of $6.34 billion, indicating a price to book ratio of 2.0417 and a price to sales ratio of 3.1109.

In the last 12-months Exelixis Inc’s revenue was $1.66 billion with a gross profit of $1.55 billion and an EBITDA of $170.31 million. The EBITDA ratio measures Exelixis Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Exelixis Inc’s operating margin was 8.84% while its return on assets stood at 3.17% with a return of equity of 6.34%.

In Q1, Exelixis Inc’s quarterly earnings growth was a negative -42.9% while revenue growth was a positive 14.8%.

Exelixis Inc’s PE and PEG Ratio

Forward PE
10.582
Trailing PE
41.4468
PEG
0.3157

Its diluted EPS in the last 12-months stands at $0.47 per share while it has a forward price to earnings multiple of 10.582 and a PEG multiple of 0.3157. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Exelixis Inc’s profitability.

Exelixis Inc stock is trading at a EV to sales ratio of 2.2582 and a EV to EBITDA ratio of 9.658. Its price to sales ratio in the trailing 12-months stood at 3.1109.

Exelixis Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$3.14 billion
Total Liabilities
$327.60 million
Operating Cash Flow
$-49592000.00
Capital Expenditure
$48.52 million
Dividend Payout Ratio
0%

Exelixis Inc ended 2024 with $3.14 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $3.14 billion while shareholder equity stood at $2.56 billion.

Exelixis Inc ended 2024 with $0 in deferred long-term liabilities, $327.60 million in other current liabilities, 325000.00 in common stock, $5.80 million in retained earnings and $63.68 million in goodwill. Its cash balance stood at $540.60 million and cash and short-term investments were $1.31 billion. The company’s total short-term debt was $0 while long-term debt stood at $0.

Exelixis Inc’s total current assets stands at $1.64 billion while long-term investments were $806.62 million and short-term investments were $772.54 million. Its net receivables were $233.92 million compared to accounts payable of $32.62 million and inventory worth $29.91 million.

In 2024, Exelixis Inc's operating cash flow was $-49592000.00 while its capital expenditure stood at $48.52 million.

Comparatively, Exelixis Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$22.09
52-Week High
$22.47
52-Week Low
$14.87
Analyst Target Price
$25.4

Exelixis Inc stock is currently trading at $22.09 per share. It touched a 52-week high of $22.47 and a 52-week low of $22.47. Analysts tracking the stock have a 12-month average target price of $25.4.

Its 50-day moving average was $20.68 and 200-day moving average was $18.66 The short ratio stood at 2.97 indicating a short percent outstanding of 0%.

Around 241.7% of the company’s stock are held by insiders while 9226.1% are held by institutions.

Frequently Asked Questions About Exelixis Inc

The stock symbol (also called stock or share ticker) of Exelixis Inc is EXEL

The IPO of Exelixis Inc took place on 2000-04-07

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$3.32
-0.12
-3.49%
$16.15
-0.53
-3.18%
$45.77
-1.15
-2.45%
$557.85
-79.6
-12.49%
$15.5
0.5
+3.33%
$73.81
-1.5
-1.99%
$0.03
0
+7.55%
$16.5
-0.1
-0.6%
$9.86
0.02
+0.2%
$7.81
0
0%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin’s lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Address

1851 Harbor Bay Parkway, Alameda, CA, United States, 94502